Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

YO19 - Vulvar Squamous Cell Carcinoma: A Case Report

Date

07 Dec 2024

Session

Poster Display session

Presenters

DOROTHY JOY BACOMO

Authors

D.J.E. BACOMO

Author affiliations

  • Medical Oncology, SPMC - Southern Philippines Medical Center, 8000 - Davao City/PH

Resources

This content is available to ESMO members and event participants.

Abstract YO19

Case summary

Introduction: Vulvar Cancer is a rare gynecologic malignancy making up 5% of all cancers of the female genital tract. We report a case of a metastatic Vulvar Squamous Cell Carcinoma in a postmenopausal female. To our knowledge, there were only 3 reported cases at Philippine General Hospital from July 16, 1945 to June 16, 1950. In Mindanao, this is the second documented case in Southern Philippines Medical Center.

Case Presentation: A 70 year old female presented with an initially painless right vulvar lesion which progressed to a tender mass associated with purulent discharge. Whole abdominal CT scan revealed a fungating, polypoid enhancing soft tissue mass protruding from the introitus, extending superiorly to the lower vaginal region. She underwent EBRT to the whole pelvis and bilateral inguinal regions (5040cGy) x 28 Fractions with noted partial response. However on reassessment, pulmonary metastasis was noted. She underwent Image-guided Brachytherapy, to complete 3 sessions and for sequential chemotherapy with Paclitaxel + Carboplatin thereafter. The patient is ongoing therapy as of this writing.

Learning Points: Treatment options for metastatic Vulvar Cancer are limited and has no standard of care. Current recommendations are mostly extrapolated from Cervical Cancer which includes concurrent chemoradiotherapy, and systemic chemotherapy. HPV testing or molecular testing is indicated to classify HPV -association. For HPV independent carcinoma, p53 is recommended. Vulvar cancer cells are known to overexpress PDL-1 and immunotherapy may be an option in patients who progress after standard chemotherapy. Independent predictors of survival include the presence and number of involved lymph nodes and primary tumor size.

Conclusion: EBRT showed partial response in patients with unresectable Vulvar Carcinoma and Brachytherapy with sequential chemotherapy (Caboplatin + paclitaxel) can be an option for postmenopausal and elderly patient after disease progression. Multimodality treatment for metastatic vulvar cancer may achieve a favorable outcome in patients.

Keywords: Vulva, Squamous cell, EBRT, Chemotherapy, Brachytherapy

Clinical trial identification

Editorial acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.